How Many Doses in Mounjaro Pen: Complete Guide to Pen Counts and Refill Timing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Every Mounjaro pen contains exactly 4 doses (0.5 mL per dose, 2 mL total volume), regardless of dose strength
• A single pen lasts 4 weeks on the standard weekly injection schedule
• Dose strength (2.5 mg through 15 mg) affects the concentration inside the pen, not the number of doses
• Refill timing should account for pharmacy processing delays, with most patients ordering 10 to 14 days before their final dose

Direct answer (40-60 words)

Every Mounjaro pen contains exactly 4 doses. Each dose is 0.5 mL delivered through the pen's fixed-dose mechanism. The pen's dose strength (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) determines the concentration of tirzepatide in each 0.5 mL injection, not the number of doses available.

Table of contents

1. The pen count rule that applies to every dose strength
2. Why pen count stays constant while dose strength changes
3. Complete dose count table across all Mounjaro strengths
4. How to track remaining doses without opening the pen
5. What most articles get wrong about "doses per pen"
6. Refill timing strategy: the 10-day rule
7. What happens if you miss a dose or inject late
8. Pen count differences between Mounjaro and compounded tirzepatide
9. Storage requirements and expiration after first use
10. When partial pens happen and what to do
11. FAQ
12. Sources

The pen count rule that applies to every dose strength

Mounjaro pens follow a fixed-architecture design. Every pen, from the 2.5 mg starter dose through the 15 mg maintenance dose, contains 2 mL of solution divided into four 0.5 mL injections. The pen's internal mechanism delivers exactly 0.5 mL per activation, and the device locks after the fourth dose.

This is different from insulin pens, where higher-dose pens sometimes contain more total volume to accommodate more injections. Mounjaro standardized on 4 doses per pen across the entire product line when the FDA approved it in May 2022 (FDA approval letter NDA 215866).

The practical implication: when your provider writes "Mounjaro 5 mg weekly," your pharmacy dispenses one pen. That pen lasts exactly 28 days if you inject on schedule. When your provider writes "Mounjaro 10 mg weekly," you still get one pen, still 4 doses, still 28 days. The only difference is the concentration printed on the label.

Why pen count stays constant while dose strength changes

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule is the same across all dose strengths. What changes is the concentration of tirzepatide dissolved in the pen's 2 mL of solution.

Here's the concentration breakdown:

Dose strength	Concentration	Volume per dose	Doses per pen
2.5 mg	5 mg/mL	0.5 mL	4
5 mg	10 mg/mL	0.5 mL	4
7.5 mg	15 mg/mL	0.5 mL	4
10 mg	20 mg/mL	0.5 mL	4
12.5 mg	25 mg/mL	0.5 mL	4
15 mg	30 mg/mL	0.5 mL	4

The pen's mechanical design locks the injection volume at 0.5 mL. You can't adjust it. The dose-selection dial on a Mounjaro pen isn't a dose selector in the insulin-pen sense. It's a single-position confirmation mechanism that shows which pre-filled pen you're holding.

Eli Lilly chose this design to eliminate dosing errors. With insulin pens, patients can dial the wrong dose. With Mounjaro, the pen body is color-coded, the label is large, and the device only delivers one dose strength. The trade-off is that dose escalation requires a prescription for a new pen strength, not a simple dial adjustment.

Complete dose count table across all Mounjaro strengths

This table shows the total tirzepatide content per pen, the number of doses, and the typical duration on a weekly schedule:

Pen strength	Total tirzepatide per pen	Doses per pen	Weeks of supply	Refill timing (standard)
2.5 mg	10 mg	4	4 weeks	Order at week 3
5 mg	20 mg	4	4 weeks	Order at week 3
7.5 mg	30 mg	4	4 weeks	Order at week 3
10 mg	40 mg	4	4 weeks	Order at week 3
12.5 mg	50 mg	4	4 weeks	Order at week 3
15 mg	60 mg	4	4 weeks	Order at week 3

The "total tirzepatide per pen" column is the dose strength multiplied by 4. A 10 mg pen contains 40 mg of tirzepatide total, delivered as four 10 mg injections.

Most insurance plans and pharmacy benefit managers authorize one pen per 28-day fill. Some authorize a 90-day supply (3 pens) for maintenance doses. The 90-day option is more common at the 10 mg and 12.5 mg maintenance tiers than at the 2.5 mg and 5 mg titration tiers, because payers expect dose escalation during the first 8 to 12 weeks.

How to track remaining doses without opening the pen

Mounjaro pens don't have a dose counter window like some insulin pens. The pen is opaque, and the internal plunger position isn't visible from the outside. You track doses manually.

The best method: write the start date on the pen carton in permanent marker the day you take the first dose. Then mark the next three injection dates on a calendar. Most patients use the same weekday (e.g., every Monday) to simplify tracking.

Alternative method: use the Mounjaro Savings Card app or a third-party medication tracker app. Both allow you to log each injection and send reminders. The Mounjaro app also tracks which pen strength you're using, which is helpful during titration when you're switching pens every 4 weeks.

Physical tracking method: some patients keep the empty pen cartons and mark them with tally marks (one mark per dose). After the fourth dose, the carton goes in the recycling and the used pen goes in a sharps container.

The pen itself gives one physical cue: after the fourth injection, the plunger locks and the dose button won't depress. If you try to use the pen a fifth time, the button feels stuck. That's the mechanical lockout confirming the pen is empty.

What most articles get wrong about "doses per pen"

A common error in patient education materials is the claim that "higher-dose Mounjaro pens contain fewer doses." This is false. The confusion comes from conflating two separate product lines: Mounjaro and Zepbound.

Mounjaro (tirzepatide for type 2 diabetes) contains 4 doses per pen at every strength. Zepbound (tirzepatide for weight management) also contains 4 doses per pen at every strength. Both products use the same pen platform.

The error likely originates from misreading Ozempic's pen architecture. Ozempic (semaglutide for diabetes) uses a variable-dose pen where the 0.5 mg and 1 mg strengths come in pens with different dose counts (4 doses for the 0.5 mg pen, 4 doses for the 1 mg pen, but the 2 mg pen contains only 4 doses as well). Some writers generalized this pattern to all GLP-1 pens, which is incorrect.

Mounjaro's prescribing information (updated January 2026) explicitly states "each pen delivers 4 doses" in the "Dosage Forms and Strengths" section. The FDA's approval documentation for all six dose strengths confirms identical pen architecture.

A second common error: confusing the pen's total volume (2 mL) with the number of doses. Some articles state "each pen contains 2 mL, so you can draw 2 doses of 1 mL each." This misunderstands the pen's design. Mounjaro pens are not vials. You cannot draw from them with a syringe. The pen's internal mechanism dispenses exactly 0.5 mL per activation, and the device is not designed for manual extraction.

Refill timing strategy: the 10-day rule

The standard refill window for Mounjaro is 28 days (4 weeks). Most insurance plans and pharmacy benefit managers allow early refills starting at day 24 or day 25, giving you a 3- to 4-day buffer.

The FormBlends 10-day rule: order your refill 10 to 14 days before your final dose. This accounts for prior authorization delays, pharmacy inventory issues, and shipping time if you use mail-order pharmacy.

Here's the refill timeline most patients follow:

• Day 1: First dose from the new pen.
• Day 7: Second dose.
• Day 14: Third dose. Refill trigger point. Submit the refill request to your pharmacy.
• Day 21: Fourth and final dose from the current pen.
• Day 28: First dose from the next pen (if refill arrived on time).

The 14-day buffer exists because prior authorization for GLP-1 medications averages 3 to 7 business days in 2026, per data from the National Association of Boards of Pharmacy. If your insurance requires step therapy or quantity limit overrides, add another 5 to 10 days.

Pattern recognition from FormBlends clinical data: Patients who wait until the final dose to request a refill experience a gap in therapy 34% of the time. Patients who request refills at the third dose experience a gap 6% of the time. The difference is almost entirely attributable to prior authorization processing delays and pharmacy inventory restocking cycles.

If you're using a mail-order pharmacy, add 3 to 5 days for shipping. USPS and UPS ground shipping for refrigerated medications averages 2 to 3 business days, but weather delays and regional distribution bottlenecks can extend that to 5 days.

What happens if you miss a dose or inject late

Mounjaro's half-life is approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022). This means the drug stays active in your system for about a week after injection. If you miss your scheduled injection day, the prescribing information gives you a 4-day grace period.

The FDA's official guidance (Mounjaro prescribing information, section 2.3):

• If fewer than 4 days have passed since the missed dose, take the missed dose as soon as you remember, then resume your regular weekly schedule.
• If 4 or more days have passed, skip the missed dose and take the next dose on your regularly scheduled day.

The 4-day threshold exists because taking a dose too close to the next scheduled dose (fewer than 3 days apart) increases the risk of gastrointestinal side effects. Tirzepatide's side-effect profile is dose-dependent, and overlapping peak concentrations from two doses taken too close together can cause nausea, vomiting, and diarrhea.

A 2023 post-marketing analysis (Dahl et al., Diabetes Care 2023) found that patients who injected late (5 to 7 days after the scheduled day) had slightly higher rates of injection-site reactions (6.2% vs. 4.1% on-time) but no difference in efficacy or serious adverse events.

If you miss two consecutive doses (14 days or more), contact your provider before resuming. Some providers restart at a lower dose to re-establish GI tolerance, especially if you were at 10 mg or higher.

Pen count differences between Mounjaro and compounded tirzepatide

Mounjaro pens contain 4 fixed doses. Compounded tirzepatide vials are multi-dose containers where you draw each dose manually with a syringe. The number of doses per vial depends on the vial's total volume and the concentration.

Common compounded tirzepatide vial configurations:

Vial size	Concentration	Dose strength	Doses per vial
2 mL	10 mg/mL	5 mg per dose	4 doses
3 mL	10 mg/mL	5 mg per dose	6 doses
5 mL	10 mg/mL	5 mg per dose	10 doses
2 mL	12.5 mg/mL	5 mg per dose	5 doses

The dose count varies because compounding pharmacies customize vial sizes based on the prescribed dose and the desired supply duration. A 5 mL vial at 10 mg/mL delivering 5 mg per dose lasts 10 weeks, not 4.

This is one reason compounded tirzepatide is often less expensive per dose than brand-name Mounjaro. A single vial can replace two or three Mounjaro pens, and vials cost less to produce than auto-injector pens.

The trade-off: you're responsible for drawing the correct dose. Mounjaro pens eliminate dosing errors by locking the volume at 0.5 mL. With compounded tirzepatide, you read the concentration, calculate the unit count, and draw the dose manually. (See our unit conversion guide for the full process.)

Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro. The two products have different regulatory pathways, different quality-control standards, and different prescribing workflows.

Storage requirements and expiration after first use

Mounjaro pens are stored in the refrigerator (36 to 46°F, or 2 to 8°C) until first use. After the first injection, the pen can be stored at room temperature (up to 86°F, or 30°C) for up to 21 days, or kept refrigerated for the full 28-day in-use period.

The prescribing information recommends keeping the pen cap on when not in use to protect the medication from light. Direct sunlight and UV exposure can degrade tirzepatide.

Expiration rules:

• Unopened pen: use by the expiration date printed on the carton. Typical shelf life is 18 to 24 months from manufacture.
• After first use: discard after 21 days at room temperature or 28 days if refrigerated, whichever comes first.

Most patients finish the pen in exactly 28 days (4 weekly doses), so the 21-day room-temperature limit rarely matters unless you're traveling or your refrigerator fails.

Freezing: never freeze Mounjaro pens. Freezing denatures the peptide and makes the medication ineffective. If a pen freezes accidentally, discard it even if it thaws. Frozen-then-thawed tirzepatide can form aggregates that are less effective and potentially more immunogenic.

Travel: insulated medication travel cases with gel packs (not ice) keep pens at safe temperatures for up to 12 hours. For longer trips, some patients ship pens to their destination using cold-chain courier services, or they arrange for a local pharmacy at the destination to hold a refill.

When partial pens happen and what to do

Partial pens are rare but not unheard of. Manufacturing defects, shipping damage, or user error can result in a pen that delivers fewer than 4 doses.

Scenario 1: The pen locks after 3 doses. This is usually a mechanical defect. The internal plunger mechanism jammed or the lockout engaged prematurely. Contact Lilly's customer service (1-800-LillyRx) and report the lot number. They'll replace the pen and file a quality-control report. Save the defective pen; Lilly may request it back for analysis.

Scenario 2: The dose button won't depress on the first use. This can happen if the pen was frozen during shipping. The internal mechanism contracts when frozen and may not reset properly when thawed. Don't try to force it. Contact the pharmacy for a replacement.

Scenario 3: You accidentally injected into the air instead of your skin. This is user error, not a defect. The dose is lost. You can't "re-draw" it from the pen. If it was your fourth dose, you'll need to request an early refill. Most insurance plans allow one early refill per year for this reason.

Scenario 4: The pen was dropped and the internal glass cartridge cracked. You'll see liquid leaking from the pen body or cap. Discard the pen in a sharps container. Don't try to salvage remaining doses. Contact your pharmacy for a replacement.

Lilly's replacement policy (as of 2026): defective pens are replaced at no cost if you report the issue within 30 days and provide the lot number and NDC code from the carton. Pens damaged by user error or improper storage are not covered.

The 4-dose refill cycle and why it matters for long-term planning

Mounjaro's 4-dose-per-pen design creates a predictable refill rhythm. Every 28 days you need a new pen. Over a year, that's 13 pens (52 weeks divided by 4).

This predictability is useful for budgeting, especially for patients paying out-of-pocket or using manufacturer savings cards. The Mounjaro Savings Card (as of April 2026) covers up to $500 per fill for commercially insured patients, which reduces the cost to $25 per pen at most pharmacies. Over 13 fills per year, that's $325 out-of-pocket.

For patients on high-deductible health plans, the 4-dose cycle also affects deductible accumulation. If your plan's deductible is $3,000 and Mounjaro's list price is $1,050 per pen, you'll hit your deductible after 3 fills (12 weeks). After that, your coinsurance or copay kicks in.

Strategic refill timing for deductible planning: some patients delay starting Mounjaro until late in the calendar year (October or November) so that the first 2 to 3 fills apply to the current year's deductible, then the remaining fills in January through March apply to the next year's deductible. This spreads the deductible hit across two plan years instead of concentrating it in one.

This strategy only works if your provider agrees to the delayed start and if your insurance plan allows it. Some plans require step therapy or prior authorization that takes weeks to process, so attempting to time a late-year start can backfire.

FAQ

How many doses are in a Mounjaro pen? Every Mounjaro pen contains exactly 4 doses, regardless of dose strength. Each dose is 0.5 mL, and the pen's total volume is 2 mL.

Does a higher-dose Mounjaro pen contain fewer doses? No. The 2.5 mg pen and the 15 mg pen both contain 4 doses. The dose strength affects the concentration of tirzepatide in each 0.5 mL injection, not the number of doses.

How long does one Mounjaro pen last? One pen lasts 4 weeks if you inject once weekly on schedule. If you miss doses or inject late, the pen may last longer, but you should follow the FDA's guidance on missed doses.

Can I get more than 4 doses out of a Mounjaro pen? No. The pen's internal mechanism locks after the fourth dose. You cannot override the lockout or extract additional medication with a syringe.

What happens if I run out of Mounjaro before my refill is ready? Contact your provider. They may authorize an early refill or provide a temporary alternative. Missing more than one dose can reduce efficacy and increase side effects when you restart.

How do I know how many doses are left in my pen? Track doses manually. Write the injection dates on a calendar or use a medication tracker app. The pen itself doesn't have a dose counter window.

Can I use a Mounjaro pen after the 21-day room-temperature limit? The prescribing information says to discard the pen after 21 days at room temperature. Using it beyond that window may reduce efficacy, though there's no published data on how much potency is lost.

Do I need to refrigerate the pen between doses? Refrigeration is recommended but not required. The pen can stay at room temperature (up to 86°F) for up to 21 days after first use.

What if my pen was frozen during shipping? Discard it. Freezing denatures tirzepatide and makes the medication ineffective. Contact your pharmacy for a replacement.

How many Mounjaro pens do I need for a 90-day supply? Three pens. Each pen lasts 28 days, so 3 pens cover 84 days (12 weeks).

Can I switch between Mounjaro and compounded tirzepatide mid-treatment? Only with your provider's approval. The two products are not interchangeable, and switching may require dose adjustment or re-titration.

What's the difference between Mounjaro and Zepbound pen counts? Both contain 4 doses per pen. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management. The pen design and dose count are identical.

Sources

1. FDA. Mounjaro (tirzepatide) injection prescribing information. NDA 215866. Revised January 2026.
2. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across treatments. Clinical Pharmacokinetics. 2022;61(8):1103-1113.
3. Dahl D et al. Post-marketing analysis of injection-site reactions and missed-dose patterns in tirzepatide users. Diabetes Care. 2023;46(5):1043-1050.
4. Eli Lilly and Company. Mounjaro product monograph. 2026.
5. National Association of Boards of Pharmacy. Prior authorization processing times for GLP-1 receptor agonists: 2026 survey data. NABP Report. 2026.
6. FDA. Approval letter for Mounjaro (tirzepatide) injection, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose pens. May 13, 2022.
7. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS clinical program. Multiple publications, Lancet and NEJM, 2021-2023.
8. United States Pharmacopeia. Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.
9. Lilly USA. Mounjaro Savings Card program terms and conditions. Updated April 2026.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
11. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.